Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature
- FAGGIANO, ANTONGIULIO
- Modica, Roberta
- NUZZO, VINCENZO
- COLAO, ANNAMARIA
- Malandrino, Pasqualino
- Agrimi, Daniela
- Aversano, Maurizio
- Bassi, Vincenzo
- Giordano, Ernesto A
- Guarnotta, Valentina
- Logoluso, Francesco A
- Messina, Erika
- Nicastro, Vincenzo
- Sciaraffia, Marcello
Publication date
January 2016
DOI Publisher
Alphamed Press ISSN
1083-7159 Citation count (estimate)
3Abstract
Everolimus, an oral mTOR (mammalian target of rapamycin) inhibitor, is currently approved for the treatment of progressive pancreatic neuroendocrine tumors (NETs). Although promising, only scattered data, often from nondedicated studies, are available for extrapancreatic NETs
Add to ORKG